Arterioscler Thromb Vasc Biol

Slides:

Advertisements

Similar presentations

Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.69 ( ) n=13 (16,228/11,279)

Advertisements

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Omega-3 Fatty Acid Blood Levels by H. Robert Superko, Scott M. Superko, Khurram Nasir, Arthur Agatston, and Brenda C. Garrett Circulation Volume 128(19):

Hypercholesterolemia Enhances Thromboembolism in Arterioles but Not Venules by Martijn A.W. Broeders, Geert Jan Tangelder, Dick W. Slaaf, Robert S. Reneman,

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Maggot Therapy for Wound Debridement: A Randomized.

Normal Arterial Anatomy of the Lower Limb and Positioning for Measurement of Ankle Systolic Pressure Used for Determining the Ankle Branchial Index (ABI)

Copyright © 2007 American Medical Association. All rights reserved.

Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.

APOC3 LOF heterozygotes have lower IVD and IHD risks due to lower RC

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

Calcification burden of the femoropopliteal artery demonstrating progression from a healthy artery with no calcification (0) to advanced calcific deposits.

Arterioscler Thromb Vasc Biol

by Hideto Sano, Kohei Hosokawa, Hiroyasu Kidoya, and Nobuyuki Takakura

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly by Toshio Ogihara, Takao Saruta, Hiromi Rakugi, Hiroaki Matsuoka,

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Regulation of Hypoxia-Inducible Genes by PGC-1α

Oxygen Therapy in Ischemic Stroke

New LINE(s) of Evidence for Genetic Regulation of Platelets

Arterioscler Thromb Vasc Biol

Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease by Ryuichi Morishita, Motokuni Aoki, Naotaka.

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Assessment of Unstable Atherosclerosis in Mice

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Effect of intervention on diastolic function.

Infusion of CSL112 increases total cholesterol efflux capacity (CEC) regardless of baseline functional apolipoprotein A-I (apoA-I) activity. Infusion of.

Arterioscler Thromb Vasc Biol

HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis

Gene Transfer of Hepatocyte Growth Factor Gene Improves Learning and Memory in the Chronic Stage of Cerebral Infarction by Munehisa Shimamura, Naoyuki.

Arterioscler Thromb Vasc Biol

by Karen Reue, Robert D. Cohen, and Michael C. Schotz

Arterioscler Thromb Vasc Biol

Blood Pressure Rhythmicity and Visceral Fat in Children With HypertensionNovelty and Significance by Anna Niemirska, Mieczysław Litwin, Janusz Feber, and.

Management of acute osteoporotic vertebral fractures: a nonrandomized trial comparing percutaneous vertebroplasty with conservative therapy Terrence.

Changes in evaluation indicators from baseline to 12 weeks per visit.

Effects of magnesium sulphate on intraoperative anaesthetic requirements and postoperative analgesia in gynaecology patients receiving total intravenous.

Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic.

The effect of gene transfer with hepatocyte growth factor for pulmonary vascular hypoplasia in neonatal porcine model Masamichi Ono, MD, PhD, Yoshiki.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Changes in clinical outcome measures over 24 months on a continuous scale in the whole SWEFOT trial population with available baseline BMI categories.

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Line graph showing mean (SEM) values for ankle pain on activity for intermittent and standard groups at baseline and week 1, 2, 3, 4, and 6 after injury.

Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product Gabriel P. Lasala, MD, FACC, Jose.

Gabor Libertiny, FRCS, Linda Hands, MS, FRCS

Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease James J. Schuler,

Presentation transcript:

Arterioscler Thromb Vasc Biol Long-Term Follow-Up Evaluation of Results From Clinical Trial Using Hepatocyte Growth Factor Gene to Treat Severe Peripheral Arterial Disease by Hirofumi Makino, Motokuni Aoki, Naotaka Hashiya, Keita Yamasaki, Junya Azuma, Yoshiki Sawa, Yasufumi Kaneda, Toshio Ogihara, and Ryuichi Morishita Arterioscler Thromb Vasc Biol Volume 32(10):2503-2509 September 12, 2012 Copyright © American Heart Association, Inc. All rights reserved.

Serial changes in parameters. Serial changes in parameters. A, Changes in ankle-branchial pressure index (ABI). B, Sizes of largest ulcers. C, Rest pain assessed with visual analog scalepain scale (VAS). D, Maximum walking distance. Data are expressed as mean±SD. For comparison between baseline and each time point, data were analyzed using Dunnett test. Asterisks indicate statistically significant. Pre indicates baseline; 2M, 6M, 12M, and 24M indicate 2, 6, 12, and 24 months, respectively, after the second injection; N.S., not significant. Hirofumi Makino et al. Arterioscler Thromb Vasc Biol. 2012;32:2503-2509 Copyright © American Heart Association, Inc. All rights reserved.

Typical examples of change in ischemic ulcers in patients. Typical examples of change in ischemic ulcers in patients. The ischemic ulcer in case no.12 was completely healed in 15 months after the second injection. Case no. 3 healed in 24 months. 2 months, 15 months, 24 months indicates 2, 15, and 24 months, respectively, after the second injection. Pre indicates before injection; TAO, thromboangitis obliterans. Hirofumi Makino et al. Arterioscler Thromb Vasc Biol. 2012;32:2503-2509 Copyright © American Heart Association, Inc. All rights reserved.